PT  - JOURNAL ARTICLE
AU  - Moustafa, Ahmed
AU  - Aziz, Ramy K.
TI  - Traces of SARS-CoV-2 RNA in the Blood of COVID-19 Patients
AID  - 10.1101/2020.05.10.20097055
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.10.20097055
4099  - http://medrxiv.org/content/early/2020/05/31/2020.05.10.20097055.short
4100  - http://medrxiv.org/content/early/2020/05/31/2020.05.10.20097055.full
AB  - The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the third virus that caused coronavirus-related outbreaks over the past 20 years. The outbreak was first reported in December 2019 in Wuhan, China, but rapidly progressed into a pandemic of an unprecedented scale since the 1918 flu pandemic. Besides respiratory complications in COVID-19 patients, clinical characterizations of severe infection cases showed several other comorbidities, including multiple organ failure (liver, kidney, and heart) and septic shock. To better understand COVID-19 pathogenesis in different human organs, we interrogated the presence of the virus in the blood, or any of its components, which might provide a form of trafficking or hiding to the virus. By computationally analyzing high-throughput sequence data from patients with active COVID-19 infection, we found evidence of only traces of SARS-CoV-2 RNA in peripheral blood mononuclear cells (PBMC), while the virus RNA was abundant in bronchoalveolar lavage specimens from the same patients. We also devised a ‘viral spike-to-actin’ RNA normalization, as a metric to compare across various samples and minimize errors caused by intersample variability in human RNA. To the best of our knowledge, the presence of SARS-CoV-2 RNA in the PBMC of COVID-19 patients has not been reported before, and this observation could suggest immune presentation, but discounts the possibility of extensive viral infection of lymphocytes or monocytes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRB was required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data was published by Xiong et al. 2020 and is publicly available through the Genome Sequence Archive with accession CRA002390. https://bigd.big.ac.cn/gsa/browse/CRA002390